Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Do you have any idea about:
how much 5% of imun stock is worth?
how imun will pay $2 million in cash when they have a small fraction of that on their balance sheet?
how many years (decades) it will take for imun to actually get to the point of producing revenues? They have zero revenues now.
how stab will stay in business with no cash and no revenues as they wait for imun to get approval and actually market anything that is part of this deal?
Well, the good news for anyone like you is that they can buy all the shares of stab they want at these bargain prices lol. It has been a bargain all the way down from $7.
Perhaps. However, it is a 400 million dollar plate......so should the stock be worth more than .28 soon? My bet is yes, a whole lot more. "Under the expected terms of the deal, Statera will receive an initial $2 million upfront payment and 5% of the issued and outstanding stock of Immune Therapeutics. Statera will also receive payments for, among other things, achievement of revenue-based milestones, new indications and royalties, in exchange for its rights to any product containing low-dose naltrexone as an active ingredient, the companies said.
In aggregate, the deal could generate over $400 million in non-dilutive payments to Statera, the company said."
Just saying....
There is a difference between being on a plate and being a possibility with numerous contingencies and financing requirements with a company with no revenues. There is a reason, actually a few of them, for stab going from $7 to 30 cents. Read and understand the financials. Also continued Nasdaq listing in jeopardy. Just saying.....
I see you. Market makers trying to use the bid to stop the price from moving up.
Absolutely! But it did allow me to buy more in the .28 range just now.... lol! Wait until this thing runs again... it should really soon IMO....look at the year chart, for goodness sakes it was over $6 last July with no 400 million dollar deal on its plate. Just saying......
Low volume price manipulation is rampant.
Seriously? Projected revenue? From a term sheet about a deal that isn't close to being done, with a company that has no revenues and little cash, for products that have yet to be approved, and contingent on imun fund raising? Lucky to stay above 5 cents.
yup! 400 mil in projected revenue... and it is at .33? This stock should be over $5 very soon.imo
Lows almost tested - about to squeeze
Absolutely!!! .50 coming
.43 looks like a heavy load of this poc.
I guess the run to .50s will continue another day, today it seems a close mid .30s is more likely
Double Bottom at 43.50 and bounce off .40 looks interesting......$$$$$!
50’s almost there! Squeeeeeeze!!! $STAB
STAB shorts
Looks like it may trend upwards to .50 and close in the .40s or mid to high .30s I feel... could be wrong... volume looks promising at over 45 million dollars traded
Creeping up to the high of day. If that breaks look out blue skies! $STAB
Crazy volume, entire float has been turned over twice, going on 3 times. Not a lot of long term believers here lol. Should be more than enough volume to let private placement holders out with breakeven and free warrants. Then this attempt at a deal will have to stand on its own merits. I wouldn't want to be holding a load of 43 cent shares right now. But maybe it will take another run at .51, who knows.
What you think is a fair estimate today... mid. 30s or .50s
Their balance sheet looks like crap. Their most recent report indicates that they're bleeding and meanwhile making acquisitions and running trials in hopes that they'll be making some breakthroughs in their research and landing big Pharma deals. I mean this is the story of all Pharma and biotechnology companies, however.... they spent ton of money on R&D and administrative costs over the past year....
Got some here too. GL
Good luck $$$$$
Loading at .43? Good luck.
Making money here love it
Lol I’m loading
It's a Pump and dump 'news' ! Imun has no cash, how will it finance? LOL!
Just a lot of noise to give those who bought the last placement at .41 and .51 a chance to dump their shares and end up with free warrants. Made it to .41, maybe a chance for .51, like I said take any short term profits as .51 should put a lid on this. jmho of course.
YOU are very, very, SMART, Bro!!!! (And, I am NOT being sarcastic.)
Watch the share price. It's not huge. It's not even a done deal. imun has the same cash problems as stab and they have no revenues. And the 5% of imun shares that are supposed to be part of this agreement if it ever gets done - any idea how much that is worth?
That’s huge
About this latest deal:
Sounds good, but deal with imun? Anyone check their financials? No revenues,little cash - I'd be quick to take profits on this news. But that's just me.
Statera Biopharma Shares Rise After Rights Deal With Immune Therapeutics
5:55 pm ET April 27, 2022 (Dow Jones) Print
By Stephen Nakrosis
Shares of Statera Biopharma Inc. were trading higher in Wednesday's after-hours market, following news the company entered a strategic agreement with Immune Therapeutics Inc. to sell rights to naltrexone and met-enkephalin.
At 5:46 p.m. ET, Statera shares were trading 52.3% higher at 31 cents each. Volume in the after-hours session topped 8.7 million shares.
The stock finished the day's regular session with a 1.23% loss, closing at just under 21 cents a share. The stock hit a 52-week low of fractionally above 20 cents a share earlier in the day.
Under the expected terms of the deal, Statera will receive an initial $2 million upfront payment and 5% of the issued and outstanding stock of Immune Therapeutics. Statera will also receive payments for, among other things, achievement of revenue-based milestones, new indications and royalties, in exchange for its rights to any product containing low-dose naltrexone as an active ingredient, the companies said.
In aggregate, the deal could generate over $400 million in non-dilutive payments to Statera, the company said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
Followers
|
79
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3504
|
Created
|
05/13/07
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |